Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by SteelPeak Wealth LLC

SteelPeak Wealth LLC boosted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 154.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,823 shares of the biopharmaceutical company's stock after purchasing an additional 1,715 shares during the quarter. SteelPeak Wealth LLC's holdings in Regeneron Pharmaceuticals were worth $2,011,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Mizuho Securities USA LLC grew its holdings in shares of Regeneron Pharmaceuticals by 625.5% during the third quarter. Mizuho Securities USA LLC now owns 59,341 shares of the biopharmaceutical company's stock worth $62,382,000 after purchasing an additional 51,162 shares during the last quarter. Principal Financial Group Inc. raised its position in Regeneron Pharmaceuticals by 1.7% in the 3rd quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company's stock valued at $181,961,000 after purchasing an additional 2,828 shares during the last quarter. Simplify Asset Management Inc. grew its position in Regeneron Pharmaceuticals by 50.8% during the 3rd quarter. Simplify Asset Management Inc. now owns 9,591 shares of the biopharmaceutical company's stock worth $10,082,000 after purchasing an additional 3,231 shares during the last quarter. Catalytic Wealth RIA LLC acquired a new position in Regeneron Pharmaceuticals in the third quarter valued at $1,334,000. Finally, Daiwa Securities Group Inc. raised its holdings in shares of Regeneron Pharmaceuticals by 12.3% in the third quarter. Daiwa Securities Group Inc. now owns 20,384 shares of the biopharmaceutical company's stock valued at $21,428,000 after buying an additional 2,234 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company's stock.

Wall Street Analysts Forecast Growth

REGN has been the topic of several recent research reports. Oppenheimer dropped their price target on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an "outperform" rating on the stock in a research report on Wednesday, November 6th. Truist Financial dropped their target price on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a "buy" rating on the stock in a report on Wednesday, January 8th. Cantor Fitzgerald reaffirmed a "neutral" rating and set a $1,015.00 price target on shares of Regeneron Pharmaceuticals in a report on Wednesday, October 23rd. Morgan Stanley dropped their price objective on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an "overweight" rating on the stock in a research note on Friday, November 1st. Finally, Wells Fargo & Company reduced their target price on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an "overweight" rating for the company in a research note on Friday, January 10th. One research analyst has rated the stock with a sell rating, seven have given a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $1,004.57.

Regeneron Pharmaceuticals Price Performance

NASDAQ:REGN traded down $4.19 during mid-day trading on Thursday, hitting $683.08. 771,262 shares of the company's stock traded hands, compared to its average volume of 885,444. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. Regeneron Pharmaceuticals, Inc. has a 1 year low of $666.25 and a 1 year high of $1,211.20. The company has a market cap of $75.06 billion, a PE ratio of 16.90, a price-to-earnings-growth ratio of 1.59 and a beta of 0.10. The firm's 50 day simple moving average is $723.36 and its 200 day simple moving average is $928.61.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.